Sonnet BioTherapeutics skyrockets 100% on FDA Expanded Access Protocol grant for RLF-100 (Aviptadil) for Respiratory Failure in COVID-19 by it’s subsidiary Relief Therapeutics.
Relief Therapeutics and its U.S. partner, NeuroRx, Inc. announced that FDA has granted NeuroRx an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide. Details may be seen on www.clinicaltrials.gov NCT04453839. The protocol makes treatment available to patients who have exhausted approved therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of other medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.
By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment, We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial.
Is Sonnet BioTherapeutics (SONN) a good buy?
Shares of Sonnet BioTherapeutics (SONN) appear to be a very good investment option, the Money Midnight Indicator™ is expecting its price to increase considerably in the next several months. The majority of the metrics point to this investment being highly attractive.
